Parkinson's Disease and Cognitive Impairment
Yang Yang1, Bei-Sha Tang2, Ji-Feng Guo2
1Department of Neurology, Xiangya Hospital, Central South University, Changsha, Hunan 410008, China; Key Laboratory of Hunan Province in Neurodegenerative Disorders, Central South University, Changsha, Hunan 410008, China.
Parkinson'S Disease
|January 7, 2017
Summary
Parkinson's disease (PD) affects more than motor skills, with cognitive impairment significantly impacting patient quality of life. This review summarizes research on PD cognitive deficits to aid clinical practice.
Area of Science:
- Neuroscience
- Neurology
Background:
- Parkinson's disease (PD) is a progressive neurodegenerative disorder primarily known for motor symptoms like tremor and rigidity.
- Emerging evidence highlights significant non-motor symptoms in PD, including cognitive impairment, autonomic dysfunction, and sleep disorders.
- Current treatments for PD predominantly address motor deficits, often overlooking cognitive impairment, which severely affects patient well-being and healthcare costs.
Approach:
- This review synthesizes recent research on the epidemiology, clinical manifestations, diagnosis, genetics, and potential treatments for cognitive deficits in Parkinson's disease.
- A retrospective analysis of existing literature was conducted to provide a comprehensive overview.
- The goal is to equip clinicians with updated knowledge to manage cognitive impairment in PD patients.
Key Points:
- Cognitive impairment, including dysexecutive syndrome and visuospatial disturbances, is a common and significant non-motor symptom in Parkinson's disease.
- These cognitive deficits substantially reduce quality of life, decrease life expectancy, and increase hospitalization duration and costs.
- Understanding the multifaceted nature of PD, beyond motor symptoms, is crucial for holistic patient care.
Conclusions:
- Cognitive impairment is a critical aspect of Parkinson's disease that requires greater clinical attention.
- This review offers a consolidated summary of current knowledge on PD-related cognitive deficits.
- The findings aim to support clinicians in effectively addressing these challenging issues in their practice.
Related Concept Videos
Parkinson's Disease: Treatment
1.3K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.3K
Parkinson's Disease: Overview
2.3K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
2.3K
Alzheimer's Disease: Overview
1.9K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.9K
Neural Regulation
43.9K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
43.9K
Alzheimer's Disease: Treatment
1.1K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.1K
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
766
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
766


